BARD1 antibody (AA 101-200) (Cy5.5)
Quick Overview for BARD1 antibody (AA 101-200) (Cy5.5) (ABIN706501)
Target
See all BARD1 AntibodiesReactivity
Host
Clonality
Conjugate
Application
-
-
Binding Specificity
- AA 101-200
-
Cross-Reactivity
- Human
-
Predicted Reactivity
- Mouse,Rat,Dog,Cow,Pig,Horse,Chicken
-
Purification
- Purified by Protein A.
-
Immunogen
- KLH conjugated synthetic peptide derived from human BARD1
-
Isotype
- IgG
-
-
-
-
Application Notes
-
FCM 1:20-100
IF(IHC-P) 1:50-200
IF(IHC-F) 1:50-200
IF(ICC) 1:50-200 -
Restrictions
- For Research Use only
-
-
-
Format
- Liquid
-
Concentration
- 1 μg/μL
-
Buffer
- Aqueous buffered solution containing 0.01M TBS ( pH 7.4) with 1 % BSA, 0.03 % Proclin300 and 50 % Glycerol.
-
Preservative
- ProClin
-
Precaution of Use
- This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.
-
Storage
- -20 °C
-
Storage Comment
- Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.
-
Expiry Date
- 12 months
-
-
- BARD1 (BRCA1 Associated RING Domain 1 (BARD1))
-
Alternative Name
- BARD1
-
Background
-
Synonyms: BRCA1-associated RING domain protein 1, BARD-1, BARD1
Background: Probable E3 ubiquitin-protein ligase. The BRCA1-BARD1 heterodimer specifically mediates the formation of 'Lys-6'-linked polyubiquitin chains and coordinates a diverse range of cellular pathways such as DNA damage repair, ubiquitination and transcriptional regulation to maintain genomic stability. Plays a central role in the control of the cell cycle in response to DNA damage. Acts by mediating ubiquitin E3 ligase activity that is required for its tumor suppressor function. Also forms a heterodimer with CSTF1/CSTF-50 to modulate mRNA processing and RNAP II stability by inhibiting pre-mRNA 3' cleavage.
-
Gene ID
- 580
-
UniProt
- Q99728
-
Pathways
- DNA Damage Repair
Target
-